RBL Communications
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
Select Page

Dominion Water Pursues Its Consolidation Of Specialty Water Market With Letter Of Intent To Acquire 13 Ppm Silicium Water Source And 25 Year Water Supply Agreement With Aquanord

Aug 18, 2020

Montreal, Quebec (August 18, 2020) – Dominion Water Reserves Corp. (“DWR”), is pleased to announces that it has entered into an arm’s length letter of intent, dated August 18, 2020, pursuant to which  DWR will acquire all of the issued and outstanding securities of...

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

Aug 14, 2020

TORONTO, Aug. 14, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has...

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

Aug 11, 2020

TORONTO, Aug. 11, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce, further...

Kontrol’s COVID-19 Technology Receives Initial Positive Lab Test Results

Aug 10, 2020

— Kontrol BioCloud® — TORONTO, ON / August 10, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) is pleased to announce that the detection mechanism of the Kontrol BioCloud® analyzer...

Kontrol Receives Approval for Government Grant to Accelerate the Development of New COVID-19 Testing Technology

Aug 5, 2020

— Kontrol BioCloud® — TORONTO, ON /  August 5, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) is pleased to announce that it has received approval for an initial government grant of $50,000 from...

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

Aug 5, 2020

TORONTO, Aug. 05, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that...
« Older Entries
Next Entries »

Follow Us

Categories

  • Al O'Grady
  • Anfield Energy
  • Blog
  • Boba Mint Holdings
  • Kontrol Energy
  • News
  • PharmaDrug
  • Revive
  • Uncategorized
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
  • Facebook
  • X
© COPYRIGHT 2025. RBL Communications Inc. ALL RIGHTS RESERVED.